Gui-Dong Zhu
Overview
Explore the profile of Gui-Dong Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
796
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu Y, Jang M, Miyashiro J, Clark R, Zhu G, Gong J, et al.
J Med Chem
. 2024 Sep;
67(19):17000-17032.
PMID: 39283694
TAM receptor tyrosine kinases have emerged as promising therapeutic targets for cancer treatment due to their roles in both tumor intrinsic survival mechanisms and suppression of antitumor immunity within the...
2.
Tong Y, Florjancic A, Clark R, Lai C, Mastracchio A, Zhu G, et al.
ACS Med Chem Lett
. 2021 Jul;
12(7):1108-1115.
PMID: 34267880
Cyclin-dependent kinase 9 (CDK9) is a serine/threonine kinase involved in the regulation of transcription elongation. An inhibition of CDK9 downregulates a number of short-lived proteins responsible for tumor maintenance and...
3.
Chen Y, Li S, Lv D, Zhu G, Wang Y, Meng X, et al.
Front Neurosci
. 2018 Dec;
12:889.
PMID: 30546294
Obsessive-compulsive disorder (OCD) patients have difficulty in switching between obsessive thought and compulsive behavior, which may be related to the dysfunction of the salience network (SN). However, little is known...
4.
Zhu G, Fu Y
Yao Xue Xue Bao
. 2013 Oct;
48(7):1053-70.
PMID: 24133971
Chemotherapy remains one of the major tools, along with surgery, radiotherapy, and more recently targeted therapy, in the war against cancer. There have appeared a plethora of highly potent cytotoxic...
5.
Zhu G, Gong J, Gandhi V, Liu X, Shi Y, Johnson E, et al.
Bioorg Med Chem
. 2012 Jul;
20(15):4635-45.
PMID: 22766219
PARP-1, the most abundant member of the PARP superfamily of nuclear enzymes, has emerged as a promising molecular target in the past decade particularly for the treatment of cancer. A...
6.
Jin G, Zhu G, Zhao Z, Liu F
Clin Exp Med
. 2011 Aug;
12(3):135-43.
PMID: 21874584
Gaucher disease is an autosomal recessive lysosomal storage disorder resulting in a deficiency of glucocerebrosidase (GC). Imiglucerase, a recombinant form of GC, has been successfully used in the treatment of...
7.
Penning T, Zhu G, Gong J, Thomas S, Gandhi V, Liu X, et al.
J Med Chem
. 2010 Mar;
53(8):3142-53.
PMID: 20337371
We have developed a series of phenylpyrrolidine- and phenylpiperidine-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase (PARP) inhibitors with excellent PARP enzyme potency as well as single-digit nanomolar cellular potency. These efforts led...
8.
Gandhi V, Luo Y, Liu X, Shi Y, Klinghofer V, Johnson E, et al.
Bioorg Med Chem Lett
. 2010 Jan;
20(3):1023-6.
PMID: 20045315
Through conformational restriction of a benzamide by formation of a seven-membered hydrogen-bond with an oxindole carbonyl group, a series of PARP inhibitors was designed for appropriate orientation for binding to...
9.
Palma J, Wang Y, Rodriguez L, Montgomery D, Ellis P, Bukofzer G, et al.
Clin Cancer Res
. 2009 Nov;
15(23):7277-90.
PMID: 19934293
Purpose: ABT-888, currently in phase 2 trials, is a potent oral poly(ADP-ribose) polymerase inhibitor that enhances the activity of multiple DNA-damaging agents, including temozolomide (TMZ). We investigated ABT-888+TMZ combination therapy...
10.
Liu X, Han E, Anderson M, Shi Y, Semizarov D, Wang G, et al.
Mol Cancer Res
. 2009 Oct;
7(10):1686-92.
PMID: 19825992
Many established cancer therapies involve DNA-damaging chemotherapy or radiotherapy. Gain of DNA repair capacity of the tumor represents a common mechanism used by cancer cells to survive DNA-damaging therapy. Poly(ADP-ribose)...